Eli Lilly’s Obesity Pill Shows Only 11% Weight Loss in Trial – Shares Drop

Eli Lilly's new obesity pill, orforglipron, has shown modest results in its latest trial, helping participants lose just 11% of their body weight over 72 weeks. While this confirms the pill’s effectiveness, it fell short of market expectations—leading to a sharp drop in the company’s stock price.

Trial Results Fall Short of the Hype

According to the clinical data, orforglipron helped users lose an average of about 25 pounds, or 11–12% of body weight. While that marks a meaningful improvement compared to placebo, it's still below the results of popular injectable drugs like Novo Nordisk’s Wegovy or Lilly’s own Zepbound, which show 15–20% weight loss in many cases.

This has led to investor disappointment, as many were expecting more dramatic results from the pill-based treatment. As a result, Lilly’s stock fell over 12% following the announcement.

Still a Step Forward in Oral Weight Loss Options

Despite the underwhelming weight loss numbers, orforglipron does bring something new to the table—it’s an oral medication, not an injection. That’s a big deal for patients who are hesitant about needles or need a more convenient option.

It also avoids the storage and cold-chain challenges that injectable drugs often face, which could make it easier to distribute in countries with limited healthcare infrastructure.

Side Effects and Safety

Common side effects included nausea, vomiting, and diarrhea—similar to other GLP-1 drugs. Around 10% of users discontinued due to side effects, but the drug did not raise liver concerns, which is a positive sign for its safety profile.

What It Means for the Market

Even though the results are modest, orforglipron could still play a vital role in the weight loss drug market. It’s easier to take, potentially cheaper to produce, and could be approved for wider use if regulators are satisfied with the safety and efficacy data.

Investor Reaction

Following the news, Lilly’s shares saw a steep drop. Meanwhile, rival Novo Nordisk's shares rose, reflecting market confidence in injectable alternatives. Investors clearly expected more, and the stock’s reaction highlights the high bar set for weight loss treatments in 2025 and beyond.

Conclusion

Lilly's orforglipron may not be the miracle pill the market hoped for, but it's a step forward in oral weight loss medication. Its ease of use and potential scalability could still make it a valuable addition to the growing obesity drug landscape.